ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1361 National Cancer Institute Html en Esophageal Cancer Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of esophageal cancer.
esophageal mucosa0.388276
Surg Gynecol Obstet0.322065
upper thoracic esophagus0.424827
Engl J Med0.487637
oesophageal cancer0.359132
esophagus extends0.400639
Gastrointest Endosc0.369631
preoperative chemotherapy0.369817
Ann Surg Oncol0.343391
Radiation Therapy Oncology0.363113
lower esophagus0.428306
randomized trial0.366127
patients0.358564
thermal ablation therapy0.326198
Coll Surg0.323431
esophageal obstruction0.464185
cervical esophagus0.414894
esophageal adenocarcinoma0.376246
endoscopic laser therapy0.333059
radiation therapy0.485551
partial esophageal obstruction0.426095
esophageal carcinoma0.425086
Malignant esophageal obstruction0.414655
et al.0.60539
esophageal cancers results0.439813
surgery versus surgery0.374104
esophageal cancer0.911438
multicenter randomized trial0.34111
Therapy Oncology Group0.366143
PUBMED Abstract0.490901
Surgical treatment0.372648
advanced esophageal cancer0.428676
locoregional esophageal carcinoma0.419242
Thorac Cardiovasc Surg0.334758
Semin Surg Oncol0.357463
definitive radiation therapy0.326973
complete esophageal obstruction0.428536
Abstract0.52332
Clin Oncol0.7331
Council Oesophageal Cancer0.337988
inoperable malignant dysphagia0.325697
junctional cancer0.327281
Minimally invasive surgery0.326119
van Sandick JW0.37682
van Lanschot JJ0.562871
chemoradiation versus surgery0.346134
esophagus0.550763
phase III trial0.333959
squamous cell carcinoma0.57882
CLICK HERE
1684 National Cancer Institute Html en Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of Gastrointestinal Stromal Tumors
imatinib response0.41821
higher-dose imatinib mesylate0.47787
imatinib therapy.0.433313
Demetri GD0.381845
TKI imatinib mesylate0.494206
KIT receptor tyrosine0.378346
KIT exon0.370015
gastrointestinal stromal cell0.41709
KIT-expressing primary GIST0.416866
small GIST tumors0.5328
gastrointestinal stromal tumour0.414558
patients0.452898
primary GIST0.421404
complete gross resection0.401005
adjuvant imatinib0.525629
gastrointestinal stromal tumor0.540132
GIST morphology0.406777
high-dose imatinib0.421288
stromal tumor resection0.405207
tyrosine kinase inhibitor0.379801
GIST patients0.413735
et al.0.374864
GIST resection0.432449
tyrosine kinase0.423999
metastatic GIST0.418294
imatinib resistance0.431916
gastrointestinal stromal tumors0.903165
recurrent GIST0.424604
imatinib mesylate0.752767
imatinib therapy0.416737
tyrosine kinase inhibitors0.389426
imatinib ultimately experience0.466343
GIST range0.411206
imatinib-resistant GIST0.405402
GIST0.738771
Abstract0.430607
common mesenchymal tumors0.369545
Clin Oncol0.46383
imatinib doses0.430101
imatinib arm0.426642
Familial GIST0.424119
indolent GIST0.42682
gastrointestinal stromal tumours0.756245
imatinib era0.421816
inoperable GIST0.404394
new GIST cases0.474154
advanced incurable GIST0.424115
postoperative adjuvant imatinib0.452036
CLICK HERE
1691 National Cancer Institute Html en Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®)–Health Professional Version Calcium, green tea, lycopene, pomegranate, selenium, soy and vitamin E have been studied for prostate cancer prevention or treatment. Read about laboratory and human studies on various prostate supplements in this expert-reviewed summary.
atypical small acinar0.591788
dietary lycopene0.5816
local-stage prostate cancer0.605358
prostate cancer cell0.611618
prostate cancer survivors0.597981
total prostate cancer0.586726
occult prostate cancer0.591218
lycopene serum concentration0.581941
lycopene intake0.604495
prostate cancer cells.0.594787
serum lycopene0.591044
hormone-refractory prostate cancer0.585389
metastatic prostate cancer0.596215
cancer prostate cells0.587339
prostate cancer incidence0.586787
prostate cancer cells0.74273
prostate cancer risk0.675977
prostate cancer patients0.695715
serum lycopene concentrations0.582255
prostate cancer aggressiveness0.585035
prostate cancer progressi0.584763
lycopene0.683385
end-of-study prostate lycopene0.623399
Prostate Cancer Prevention0.597202
serum psa levels0.589012
human prostate cancer0.61272
plasma lycopene levels0.594142
study0.645275
androgen-independent prostate cancer0.585034
prostate cancer development0.59941
nonmetastatic prostate cancer0.584711
-resistant prostate cancer0.587482
high-grade prostate cancer0.596056
Prostate CAncer Therapy0.605352
prostate cancer mortality0.5969
prostate cancer biomarkers0.590502
prostate cancer cases0.586568
prostate lycopene concentration0.627986
green tea0.644093
prostate cancer patients.0.585445
lycopene blood levels0.586499
prostate cancer0.954937
prostate cancer.0.620441
aggressive prostate cancer0.587452
prostate cancer risk.0.60813
prostate cancer progression0.591862
prostate lycopene concentrations0.629097
lycopene levels0.595352
small acinar proliferation0.592927
CLICK HERE
1906 National Cancer Institute Html es Tratamiento de la leucemia linfocítica crónica (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfocítica crónica.
origen judío ruso0.422021
siguientes procedimientos0.424569
células madre0.989491
estadio iv0.439551
siguientes aspectos0.415966
proteína llamada bcl20.417559
leucemia linfoblástica aguda0.524325
hueso compacto0.45509
neoplasias mieloides0.413049
rayos x0.41087
Chronic Lymphocytic Leukemia0.453986
estadios i0.422864
enlace drugs approved0.452281
célula madre mieloide0.477075
células mieloides0.465027
células t0.445647
células anormales.ampliar aspiración0.467907
National Cancer Institute0.4112
sexo masculino0.412514
Instituto Nacional0.418791
LLC mejora0.413093
célula madre linfoide0.435741
PDQ Tratamiento0.432911
exploración tep0.412807
siguientes problemas0.415002
presente sección0.408632
leucemia mielógena0.445228
explorador tep0.413444
tirosina cinasa0.45926
Physician Data Query0.439508
estadio iii0.439039
linfocitos t0.431485
laboratorio piezas0.414056
Antecedentes familiares0.410684
leucemia mieloide aguda0.50943
célula madre0.588281
células sanguíneas maduras0.551856
gen igvh0.469992
siguientes sumarios0.426268
siguientes pruebas0.415779
CLICK HERE
1910 National Cancer Institute Html es Tratamiento de los tumores carcinoides gastrointestinales (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento de los tumores carcinoides gastrointestinales.
tejido tumoral carcinoide0.303641
electrodos minúsculos0.300961
tumor carcinoide0.379006
siguientes procedimientos0.32226
pequeña cámara0.300969
pequeña cantidad0.300995
claro cuál0.301673
rayos x0.301155
tumores carcinoides gi0.541315
cromogranina a0.301286
ondas sonoras0.301178
síndrome carcinoide0.405552
pequeño efecto0.300747
tumores neuroendocrinos0.31718
National Cancer Institute0.300501
tumores carcinoide gi0.305034
siguientes riesgos0.300555
endocrina múltiple tipo0.30275
Instituto Nacional0.300956
PDQ Tratamiento0.301284
neurofibromatosis tipo0.301611
tubo gi0.311684
Physician Data Query0.302032
pimientos chili0.300797
carcinoides gi recidivantes0.302839
Antecedentes familiares0.301159
cuerpo cantidades0.303122
hígado ayuda0.301344
tumores carcinoides0.989957
tumor carcinoide gi0.311705
siguientes sumarios0.303432
células neuroendocrinas0.30282
CLICK HERE
1928 National Cancer Institute Html es Tratamiento de los tumores de células germinativas del ovario (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento de los tumores de células germinativas del ovario.
células cancerosas destruyéndolas0.567328
siguientes procedimientos0.5945
estadio iv0.763261
ovarios causa efectos0.720865
siguientes tipos0.44103
rayos x0.435181
estadio ic0.701359
estadio ib0.706097
estadio ia0.703099
enlace drugs approved0.444726
Fallopian Tube0.427273
células reproductoras0.578706
área anormal.ampliar examen0.456393
peritoneal primario0.43365
estadio iva0.49879
National Cancer Institute0.427112
Instituto Nacional0.496637
estadio iiia0.688436
PDQ Tratamiento0.459552
ligera presión0.438027
estadio iiic0.681996
ganglios linfáticos detrás0.589451
estadio iia0.703376
células madres0.693148
cortará pequeños trozos0.469591
presente sección0.423353
estadio iic0.591971
Physician Data Query0.497349
or primary peritoneal0.449903
estadio iii0.989912
Nuevas opciones0.42339
siguientes situaciones0.508188
histerectomía abdominal0.832509
siguientes pruebas0.525524
siguientes sumarios0.47228
corto tiempo0.424715
siguientes estadios0.515179
CLICK HERE
3427 National Cancer Institute Html es Terapia láser para el tratamiento del cáncer Hoja informativa que describe el uso de una luz de alta intensidad en el tratamiento del cáncer, sus ventajas y desventajas, y los tipos de procedimientos que la utilizan.
usa calor0.497681
luz solar0.504529
terapia láser usa0.846675
usa rayos0.615014
sustancia fotosensibilizadora0.467924
alta intensidad0.607112
terapia láser causa0.851667
áreas minúsculas0.473045
determinados síntomas0.470796
CLICK HERE
16146 National Cancer Institute Html es Virus de la enfermedad de Newcastle (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos sobre el uso del virus de la enfermedad de Newcastle (VEN) como tratamiento para las personas con cáncer.
tumor cell immunogenicity0.407212
Cancer Res Clin0.40874
active specific immunotherapy0.409234
abstract from0.408151
with newcastle0.446575
with virus-modified0.40752
oncolytic virus0.412098
Reichard KW0.412175
with virally modified0.408993
treated postsurgically with0.409032
Cancer Res0.456074
Schirrmacher V0.472403
Csatary LK0.410713
virus selectively kills0.408217
Natl Cancer Inst0.453624
human tumor0.419154
immunotherapy with0.411294
Attenuated veterinary virus0.408258
Ahlert T0.417009
patients with0.422834
autologous tumor cells0.443634
immunotherapy with virally0.409777
immunization with0.407432
Lorence RM0.416992
modified autologous tumor0.409356
newcastle disease virus0.990705
virus infeccioso destrucción0.419778
Lítica Virus0.418733
virus as0.414895
tumor cell modification0.407198
tumor cells0.594311
virus therapy0.428512
specific immunotherapy0.411581
postsurgically with newcastle0.414603
Cassel WA0.412481
tumor vaccines0.414853
Clin Oncol0.407495
patient with0.407334
virus mutant with0.411813
after local newcastle0.411338
postoperative immunotherapy with0.409993
malignant melanoma patients0.409365
with tumor cells0.411774
renal cell carcinoma0.40842
malignant melanoma0.414222
tumor necrosis0.410434
in vitro0.430542
virus is reviving0.408425
active specific0.412889
CLICK HERE
16653 National Cancer Institute Html en IOTF Mentors: Track 3 and Track 4 While at FDA, fellows are assigned a mentor who is a senior member of FDA scientific review staff. Learn more about mentors for Tracks 3 and 4.
regulatory review0.859055
Radiological Health0.80074
review process0.801152
project0.796601
radiation therapy devices0.823079
office0.805677
Biologics Evaluation0.882543
research0.878646
therapy medical products0.786754
medical products0.814349
division0.805276
cell-based medical products0.805668
Biotechnology Products0.814932
research program0.805393
cell culture cells0.78633
gene therapy products0.878795
stem cells0.79941
development0.787013
cancer risk assessment0.792173
gene therapy0.961714
nucleic acid0.824416
investigational new drug0.905511
drug applications0.79082
new drug products0.789184
neoplastic cell substrates0.79142
radiation therapy0.854476
cancer chemotherapy0.787392
radiation therapy treatments0.789697
FDA0.8111
Drug Evaluation0.832004
Drug Administration0.845645
cell0.852835
therapeutic proteins0.875837
cell therapy0.796306
regulatory review scientist0.807408
iotf fellow0.867768
Principal Investigator0.803321
Center0.786741
early cancer detection0.787952
Cancer Health Claims0.787284
gene therapies0.879766
cells0.826854
immune cell activation0.789452
fellow0.909256
gene therapy applications0.81743
cancer risk0.812916
new medical products0.802617
cancer0.939352
CLICK HERE
16864 National Cancer Institute Html es Selected Vegetables y Sun's Soup (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos sobre el uso de Selected Vegetables y Sun's Soup como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.
Frozen SV0.301838
Sun’s Soup0.622837
Selected Vegetables0.989854
specific dietary supplement0.365272
multi-institutional prospective study0.301068
Wang LH0.31046
Sun Farm0.310084
Instituto Nacional0.303518
peso corporal promedio0.301106
IV non-small0.334303
Estados Unidos0.309279
tratamiento simultáneoc puntaje0.301389
Sun’s Soup“0.302908
allium cepa l0.300921
patients taking0.307016
non-small cell lung0.365258
Lentinus edodes0.303332
Sun Farm Corporation0.305751
frijol mungo0.301357
alimentario selected vegetables0.303781
patients with0.301382
investigación clínica0.301025
glycine max l0.300858
Yeh HC0.310747
herbal treatment0.309558
crataegus oxyacantha l0.300911
Trademark Office0.305198
puntaje promedio0.304049
allium bakeri regel0.300852
estadio iv0.311573
Sun's Soup0.425399
Pilot study0.310803
glycyrrhiza glabra l0.300901
cáncer número0.301303
frijoles mungo0.303086
Nutr Cancer0.335867
US Patent0.318672
Ryznar V0.306737
Farm Vegetable Soup0.306615
Ostadal O0.306698
accessed april0.311866
porcentaje promedio0.301352
allium fistulosum l0.300943
Glycine max0.301356
Freeze-dried SV0.300819
sesamum indicum l0.300901
pacientes sí0.303642
phaseolus radiatus l0.305677
República Checa0.301327
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.